Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
A Rule 144 filer plans to sell 3,148 common shares of an issuer with ticker PTCT through Fidelity Brokerage Services LLC. The planned sale has an aggregate market value of 240,905.34, is listed under the NASDAQ exchange, and is targeted for 01/08/2026.
The shares to be sold were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation. The notice also lists earlier sales by Eric Pauwels over the past three months, including 40,290 common shares sold on 12/17/2025 for 3,038,755.33, along with several smaller transactions in December 2025 and early January 2026.
A PTCT shareholder, Matthew Klein, filed a Form 144 notice to sell PTCT common stock under Rule 144. The notice covers 2,514 common shares to be sold through Fidelity Brokerage Services LLC on or about 01/08/2026 on the NASDAQ market. These shares were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation.
The filing also lists prior PTCT common stock sales by Matthew Klein during the past three months, including 3,428 shares sold on 12/02/2025 for gross proceeds of $271,062.93 and 8,089 shares sold on 12/30/2025 for $619,921.55, along with additional sales on 01/06/2026 and 01/07/2026.
PTCT has a Form 144 notice covering the intended sale of 59 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $4,510.50 and an approximate sale date of January 8, 2026.
The 59 shares were acquired on January 7, 2026 via restricted stock vesting from the issuer as compensation. The filing also lists recent sales in the past three months by individuals named Neil G. Almstead and Zheng Y. Almstead, including 35,572 shares sold on November 24, 2025 for $2,852,153.65, 71,928 shares on November 25, 2025 for $6,001,524.59, and several smaller transactions on January 6–7, 2026 with proceeds ranging from $4,029.16 to $98,415.98.
An insider has filed a notice of intent to sell 881 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 67,351.66. The issuer reports 80,288,305 shares of this class outstanding, and the approximate sale date is 01/08/2026 on NASDAQ.
The 881 shares to be sold were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Neil G. Almstead has sold multiple blocks of common shares, including 35,572 shares on 11/24/2025 for 2,852,153.65, 71,928 shares on 11/25/2025 for 6,001,524.59, 1,279 shares on 01/06/2026 for 98,415.98, and 1,026 shares on 01/07/2026 for 79,498.38. Zheng Y. Almstead sold 54 shares on 01/06/2026 for 4,155.17 and 52 shares on 01/07/2026 for 4,029.16.
An affiliate of PTCT filed a notice of proposed stock sales under Rule 144. The filer intends to sell 1,454 shares of common stock through Fidelity Brokerage Services LLC on or about 01/08/2026, with an indicated aggregate market value of $111,156.99. These shares relate to restricted stock that vested on 01/07/2026 and were received as compensation from the issuer on that date.
The notice also lists prior sales over the last three months by Eric Pauwels, including multiple transactions in common stock between 12/17/2025 and 01/07/2026 with individual gross proceeds such as $3,038,755.33 and $1,584,387.54. The filing states that the person for whose account the securities are to be sold represents that they are not aware of undisclosed material adverse information about the issuer’s operations.
An affiliate of PTCT has filed a Form 144 notice to potentially sell 1,034 shares of common stock through Fidelity Brokerage Services on 01/08/2026, with an aggregate market value of $79,048.37. The filing notes that 80,288,305 shares of common stock were outstanding and that the shares to be sold arose from restricted stock vesting on 01/07/2026 as compensation from the issuer.
Over the prior three months, the same seller, Christine Utter, reported selling 1,381 shares of common stock for gross proceeds of $106,264.64 on 01/06/2026 and 1,235 shares for $95,692.49 on 01/07/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s operations.
PTC Therapeutics insider files to sell additional shares under Rule 144. The filing covers a planned sale of 1,286 shares of common stock through Fidelity Brokerage Services on or about 01/08/2026, with an aggregate market value of approximately $98,313.54. These shares were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation.
Over the past three months, Mark Boulding has already sold 11,696 shares of common stock in four transactions, generating total gross proceeds of about $896,531.96. The notice also confirms that the seller represents not knowing any undisclosed material adverse information about the issuer’s operations.
A holder named Mark Boulding has filed a notice under Rule 144 to sell 2,747 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 210,447.74. The shares are listed on NASDAQ and the approximate sale date is 01/08/2026.
The 2,747 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller disposed of common shares in multiple transactions: 2,812 shares on 11/17/2025, 2,266 shares on 01/05/2026, 1,739 shares on 01/06/2026, and 4,879 shares on 01/07/2026, for gross proceeds of 213,690.35, 171,190.18, 133,811.88, and 377,839.55, respectively.
PTC Therapeutics insider Matthew Klein has filed a Form 144 indicating an intent to sell 3,016 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. The shares, with an aggregate market value of $233,691.14, were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.
Over the prior three months, Klein reported additional sales of the issuer’s common stock, including 3,428 shares on 12/02/2025 for gross proceeds of $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about PTC Therapeutics.
Form 144 discloses a planned sale of 3,376 common shares of the issuer’s stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 01/07/2026. The shares have an indicated aggregate market value of $261,381.58, and the issuer has 80,288,305 common shares outstanding.
The shares to be sold were acquired on 01/07/2026 via an option granted on 01/07/2022, with the purchase price paid in cash. Over the prior three months, the seller, Mark Boulding, reported additional sales of common shares: 3,375 shares for $214,094.81 on 10/07/2025, 2,812 shares for $213,690.35 on 11/17/2025, 2,266 shares for $171,190.18 on 01/05/2026, and 1,739 shares for $133,811.88 on 01/06/2026.